Entering text into the input field will update the search result below

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Jul. 06, 2022 3:24 PM ETHumanigen, Inc. (HGEN)By: Dulan Lokuwithana, SA News Editor1 Comment

Detailed and scientifically accurate 3D model of the SARS-CoV-2 virus at atomic resolution

Creative Thinking/iStock via Getty Images

  • Clinical-stage biotech Humanigen (NASDAQ:HGEN) rose more than 10% on Wednesday after the company announced a peer-reviewed publication of data supporting its investigational COVID-19 therapy lenzilumab.
  • The publication in the medical journal Thorax was based

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Downtown10 profile picture
Top line results expected from the NIH for the Lenzilumab ACTIV-5 trial in July. Stock is on life support (ECMO?), but it’s not dead yet. Needs to get Lenzilumab approved somewhere. I’m not optimistic about the FDA given their Big Pharma bias.

About HGEN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Humanigen, Inc.
Biocept, Inc.
SQZ Biotechnologies Company
ContraFect Corporation
Athersys, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.